Visgenx is developing therapeutics to protect against the loss of sight from retinal disorders. Our programs are based on increasing the expression of a gene known as ELOVL2 which may regulate aging in cells critical for vision.
Age-related Macular Degeneration / Geographic Atrophy
Our fast-to-market approach is based on epigenetic rescue of ELOVL2 using decitabine. Our longer term goal is ELOVL2 gene therapy.